RxDoctor Payments Data

Clinton Heyer

Podiatrist · Indianapolis, INNPI 1881219913

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Stryker at 38.2% of the total. Reporting peaked in 2023 at $3,307 and has fallen 54.4% since, to $1,508 in 2025.

$8,112in general payments, 2019–2025

Across 120 payments — averaging $67.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Skye Orthobiologics LLC$2K
  • Johnson & Johnson$1K
  • Crossroads Orthopedics, LLC$997
  • Integra Lifesciences Corporation$526
  • Arthrex$478
  • plus $505 from 5 others
$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Skye Orthobiologics LLC$2K

What the payments were for

  • Speaking & faculty fees$1,50018%
  • Travel & lodging$2,22027%
  • Food & beverage$4,39254%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,112 in reported general payments places this provider in the 85th percentile of 131 podiatrist providers in Indiana.

See all podiatrist providers in Indiana

Medicare billing

Part B allowed, 2024
$75,303
Medicare patients
332
Services billed
1,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen42$392
Doxycycline Monohydrate15$285
Terbinafine Hcl16$217
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$148
Doxycycline Hyclate12$107
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$75
Meloxicam17$55

Paid to pharmacies, not to this prescriber.

Other podiatrist in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →